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The presence of an “isolated viral capsid antigen (VCA) IgG” pattern in serum is not easy to interpret without the aid of further
tests, such as speciﬁc immunoblotting or a virus genome search, that often give rise to organisational and economic problems.
However, one alternative is to use an enzyme-linked immunosorbent assay (ELISA) to detect anti-early antigen (EA) antibodies,
which can be found in about 85% of subjects with acute Epstein-Barr virus (EBV) infections. The purpose of this work was
to search for anti-EA(D) antibodies in 130 samples with an isolated VCA IgG pattern at ELISA screening and classiﬁed as being
indicativeofpast(102cases)oracute(28cases)infectiononthebasisoftheimmunoblottingresults.Thirty-sevensamples(28.5%)
were positive for anti-EA(D), of which 25 (89.3%) had been classiﬁed by immunoblotting as indicating acute and 12 (11.8%) past
EBV infection. This diﬀerence was statistically signiﬁcant (P<. 01). The results of our search for anti-EA(D) antibodies correctly
identiﬁed nearly 90% of acute (presence) or past EBV infections (absence). When other tests are not available, the search for
anti-EA antibodies may therefore be helpful in diagnosing patients with an isolated VCA IgG pattern at screening tests.
1.Introduction
The most common manifestation of primary Epstein-Barr
virus (EBV) infection is acute infectious mononucleosis, a
self-limited clinical syndrome that most frequently aﬀects
adolescents and young adults. Serology is one of the cardinal
means of diagnosing EBV infection as antibody search for
viral capsid antigen (VCA), nuclear antigen (EBNA), and
early antigen (EA) makes it possible to deﬁne the status of
the infection [1, 2]. The three parameters of VCA IgG, VCA
IgM,andEBNA-1IgGgenerallymakeitsimpletodistinguish
acute and past infection in immunocompetent patients [3].
The presence of VCA IgG and VCA IgM in the absence of
EBNA-1 IgG is indicative of acute infection, whereas the
presence of VCA IgG and EBNA-1 IgG in the absence of VCA
IgM is typical of past infection.
However, the presence of an isolated VCA IgG pattern
m a ya p p e a ri na b o u t8 %o fa l ls u b j e c t sw i t ha tl e a s to n e
EBV infection marker [4]a n dm a yb ed i ﬃcult to interpret
because it can be found in patients with prior infection as
well as in those with acute infection. In fact, in some cases,
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short time, or at such a low concentration as to be missed
by conventional laboratory tests [5]; furthermore, VCA IgM
may persist for a long time after acute infection and still
be detected after 80 weeks together with EBNA-1 IgG. The
picture is made even more complicated by the fact that 5%
of patients produce no EBNA IgG after EBV infection [5, 6]
and, even when it is actually produced, it may be lost over
time especially in the case of immunosuppression [5, 7, 8].
In such cases, in addition to following up the patient in order
to evaluate possible variations in antibody titres, it is useful
to perform further laboratory tests such as immunoblotting
for various speciﬁc IgG antibodies, a VCA IgG avidity test,
or searches for heterophile antibodies or viral genome using
molecular biology techniques [9]. Tests such as a viral
genome search or immunoblotting are particularly useful
for deﬁning the status of infection [10–12]. In particular,
immunoblotting [13] using recombinant antigens such as
p72 (EBNA-1), p18 (VCA), p23 (VCA), p54 (EA), p1382 International Journal of Microbiology
Table 1: Antibody speciﬁcity at EBV immunoblotting in 103 samples with an isolated VCA IgG pattern at ELISA screening.
No. Anti-EBV immunoblotting
gp250/350 p54 p72 p138 p23 p18 Infection
102 27 (26.5%) 16 (15.7%) 65 (63.7%) 30 (29.4%) 99 (97.1%) 102 (100%) Past
28 6 (21.4%) 27 (96.4%) 0 (0%) 26 (92.9) 21 (75.0%) 0 (0%) Acute
Table 2: Results of search for anti-EA(D) antibodies in relation to
results of anti-EBV immunoblotting.
Anti-EBV immunoblotting Anti-EA(D) antibodies
Negative Positive Total
Anti-p18 negative (acute infection) 3 (10.7%) 25 (89.3%) 28
Anti-p18 positive (past infection) 90 (88.2%) 12 (11.8%) 102
(EA), and gp350/250 (MA = membrane antigen) can detect
anti-VCA p18 antibodies which, as they are produced
late during the course of EBV infection, are considered
substitutes for EBNA-1 IgG [7]. Unfortunately, economic
and organisational problems still limit the widespread use of
this and molecular biology techniques.
One possible alternative is to look for an additional
serological marker that can be easily detected by means
of ELISA cases, such as anti-early antigen (EA) antibodies.
These consist of a diﬀuse (D) and restricted component (R)
that reﬂect the two diﬀerent patterns originally observed
using immunoﬂuorescence. About 70%–85% of patients
with acute EBV infection are anti-EA(D) antibody positive
for up to three months after symptom onset [7, 14].
However, high titres of these antibodies are present during
EBV reactivation [15] and in patients with nasopharyngeal
carcinoma [16], and they can also be found in 20%–30%
of healthy subjects with a history of EBV infection [17, 18].
Consequently, a search for anti-EA(D) antibodies alone does
not make it possible to identify any stage of the disease [9],
but its combination with other parameters may be useful
for making a laboratory diagnosis of acute EBV infection
[19]. A recent study showed a pattern of VCA IgG positive
and VCA IgM, EBNA-1 IgG, and anti-EA(D) IgG negative
(and heterophile antibody negative) as associated with past
infection, while a pattern of VCA IgG and anti-EA(D) IgG
positive but VCA IgM and EBNA-1 IgG negative has a still
unclear meaning [20].
The aim of this study was to evaluate the usefulness of
an ELISA for anti-EA(D) antibodies in subjects with isolated
VCA IgG (VCA IgG positive and VCA IgM and EBNA-1 IgG
negative) at ELISA screening, typed as being indicative of a
past or acute infection on the basis of immunoblotting.
2.MaterialandMethods
One hundred and thirty serum samples were selected with
an isolated VCA IgG pattern (VCA IgM and EBNA-1 IgG
negative, but VCA IgG positive) at ELISA screening. The
samples came from 69 females and 61 males (mean age 32.9
years, range 3–88) with suspected EBV infection and were
sent by general practitioners to the Microbiology Unit of
Legnano Hospital to be searched for speciﬁc antibodies.
In our Unit, ELISA routine screening includes the
simultaneoussearchofVCAIgG,VCAIgM,andEBNA-1IgG
(ETI-VCA-G, ETI-EBV-M reverse, ETI-EBNA-G, DiaSorin,
Saluggia, Italy) and in case of isolated VCA IgG, an EBV
immunoblotting (RecomBlot EBV IgG, Mikrogen, Neuried,
Germany) is performed.
On the basis of the presence or absence of anti-p18
at immunoblotting, all samples were divided into 102
cases with past and 28 with acute infection (Table 1).
They were also tested for the presence of heterophile
antibodies (MonoSlide, Diesse, Siena, Italy) and anti-EA(D)
antibodies, using an ELISA (ETI-EA-G, DiaSorin, Saluggia,
Italy). Recombinant polypeptide antigen (47kDa) used in
ELISA is correlated to the recombinant p54 antigen of
immunoblotting. The data were statistically analysed using
Fisher’s exact test and the χ2 test.
3. Results
Thirty-seven samples (28.5%) were positive and 93 (71.5%)
negative for anti-EA(D). Among the cases classiﬁed by
immunoblottingasindicatingacuteorpastEBVinfection,25
(89.3%) and 12 (11.8%) were respectively positive for anti-
EA(D) (Table 2). This diﬀerence was statistically signiﬁcant
(P<. 01).
Among the 28 cases with acute infection at immunoblot-
ting, 16 (57.1%) had heterophile antibodies and, of these, 15
(93.8%) were positive for anti-EA(D) antibodies.
Table 3 shows the correlation between anti-EA(D) posi-
tivity andindividual antibody speciﬁcity atimmunoblotting.
Thediﬀerenceswerestatisticallysigniﬁcantinthecaseofp54,
p72, p138, and p18 (P<. 01).
4. Discussion
The presence of an isolated VCA IgG serological pattern is
not easy to interpret because it can be found in patients with
prior EBV infection who have lost or never shown EBNA-
1 IgG as well as in those with acute infection in whom
VCA IgM appears late or disappears early. However, it is
important to be able to interpret this pattern correctly when
a laboratory needs to quickly respond to questions of the
clinicians. Without having to wait for a second sample in the
hope of a change in the antibody pattern, it would seem to
be useful to use a further marker in addition to the three
routine tests (VCA-IgG, IgM and EBNA-1 IgG). Given that
immunoblotting or a search for virus genome can create
organisational and economic problems, an easily automatedInternational Journal of Microbiology 3
Table 3: Correlations between the presence of anti-EA(D) antibodies and antibody speciﬁcity at EBV immunoblotting.
Anti-EA(D) No. Anti-EBV at immunoblotting
antibodies gp250/350 p54 p72 p138 p23 p18
Positive 37 11 (29.7%) 34 (91.9%) 7 (18.9%) 32 (86.5%) 32 (86.5%) 12 (32.4%)
Negative 93 22 (23.7%) 13 (14.0%) 58 (62.4%) 24 (25.8%) 89 (95.7%) 92 (98.9%)
P NS <.01 <.01 <.01 NS <.01
NS: not signiﬁcant.
test such as an ELISA, whose costs are comparable with those
of other screening tests, could be a viable alternative.
Anti-EA(D) antibodies could make a useful marker
because they are normally present during the acute phase,
even though they are not always produced and sometimes
remain for a long time after the primary infection (their
presence has been reported in 20%–30% of patients with
past infections) [17, 18]. We found them in about 12% of
our patients with an isolated VCA IgG pattern and a past
infection identiﬁed by means of immunoblotting, but in
90% of those with an acute infection. Compared to more
recent studies in literature [20], if our study is concordant
in indicating, in this group of patients, the absence of anti-
EA(D) IgG as mark of past infection, on the other hand
the presence of anti-EA(D) IgG correlates with an acute
infection.
In conclusion, the results of our search for anti-EA(D)
antibodies correctly identiﬁed nearly 90% of acute (presence
of anti-EA(D)) or past EBV infections (absence of anti-
EA(D)), which indicate that, in laboratory routine, it can
be helpful in diagnosing immunocompetent patients with
an isolated VCA IgG pattern when other more sophisticated
tests are not available.
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